Larynx Clinical Trial
Official title:
Pilot Study of Metformin in Head and Neck Cancer and Its Effect on Proinflammatory Cytokines and Exosomes Implicated in Acute and Chronic Toxicity
Verified date | December 2020 |
Source | Thomas Jefferson University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissues.
Status | Completed |
Enrollment | 9 |
Est. completion date | July 31, 2020 |
Est. primary completion date | July 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Subjects with a diagnosis of head and neck cancer biopsy proven, and who are candidates for radiation therapy - All subjects must be able to comprehend and sign a written informed consent document. Exclusion Criteria: - Subjects who are pregnant or may become pregnant during metformin administration; pregnancy testing will be done in conjunction with preradiation protocols - Subjects on metformin for any reason during the preceding 4 weeks - Diabetic subjects are eligible if they are not taking metformin or insulin - Subjects who have received iodinated contrast dye must wait 12 hours prior to starting Metformin. If a CT scan with contrast is scheduled after screening and consent, the metformin cannot be taken until after the CT with contrast has been completed and they have waited 12 hours. - Patients with plasma creatinine level greater than 1.3 mg/dL - Patients with plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis - Patients with history of congestive heart failure - Patients with myocardial ischemia or peripheral muscle ischemia - Patients with sepsis or severe infection - Patients with history of lung disease currently requiring any supplemental oxygen treatment - Patients scheduled for radiation less than 6 days from enrollment - Patients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests; patients who have a history of hepatic dysfunction or hepatic disease and normal liver function tests will be eligible to participate - Patients with a current history (in the past 30 days) of heaving drinking which is defined in accordance with CDC definition as more than 8 drinks per week for women and more than 15 drinks per week for men. A standard drink contains .6 ounces of pure alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). While on study, patients should limit their alcohol consumption to no more than 8 drinks per week for women and no more than 15 drinks per week for men. Patients who feel they cannot comply with this recommendation are not eligible". - All medications are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations |
Country | Name | City | State |
---|---|---|---|
United States | Sidney Kimmel Cancer Center at Thomas Jefferson University | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Cancer Center at Thomas Jefferson University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cytokine/Chemokine Profile | Mixed effects linear regression will be used to model longitudinal measurements of each cytokine. | Up to 1 year | |
Secondary | Mucositis Assessed Using WHO Classification | Analysis will be primarily descriptive. The distribution of swallowing function and mucositis scores will be summarized by arm using means, medians, standard deviations, and ranges. | Up to 1 year | |
Secondary | Objective Response Rate | The objective response rate will be estimated by arm along with an exact 95% binomial confidence interval | Up to 2 years | |
Secondary | Exosome Profile | Longitudinal measurements of exosomes will also be modeled using mixed effects linear regression. This analysis is treated as separate from the cytokine questions and the p-value will not be adjusted. | Up to 1 year | |
Secondary | Incidence of Toxicities | Evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05746780 -
Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
|
||
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Completed |
NCT02126969 -
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
|
Phase 2 | |
Completed |
NCT01263873 -
Examining the Ease of Intubation Using the Parker Flex-Tip® or a Standard Endotracheal Tube
|
N/A | |
Completed |
NCT03162731 -
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
|
Early Phase 1 | |
Enrolling by invitation |
NCT03269396 -
Laryngeal Allograft Transplantation
|
N/A | |
Completed |
NCT01649973 -
Study for Appropriate Operating Table Height for Endotracheal Intubation Under Direct Laryngoscopy
|
N/A | |
Withdrawn |
NCT04168671 -
CLE During Exercise Testing in Asthma
|
N/A | |
Completed |
NCT01321892 -
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
|
N/A | |
Recruiting |
NCT05636410 -
Ultrasound Assessment of the Larynx and Trachea in the Neonatal Period
|
||
Recruiting |
NCT05565430 -
Vocal Cord Responses During Hyperventilation in Normal Individuals and in Mild and Severe Asthmatics.
|
||
Active, not recruiting |
NCT03737968 -
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
|
Phase 2 | |
Recruiting |
NCT03109171 -
Accuracy of the Sensory Test Using the Laryngopharyngeal Endoscopic Esthesiometer in Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT02761239 -
Innervation of Human Cricopharyngeal Muscle By Recurrent Laryngeal and External Branch of Superior Laryngeal Nerve
|
N/A | |
Recruiting |
NCT05145556 -
Teach Intubation by Novices in Anaesthesiology
|
N/A | |
Completed |
NCT03030781 -
Relationship of Cricoid With the Right and Left Bronchial Diameters in the Pediatric Population Using Three-dimensional Imaging.
|
N/A | |
Completed |
NCT03238365 -
Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Early Phase 1 | |
Withdrawn |
NCT02065128 -
The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome
|
N/A | |
Active, not recruiting |
NCT03854032 -
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT03076281 -
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
|
Phase 2 |